Fangzhou Inc (HK:06086), a Chinese online chronic disease management platform, announced on Monday the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI) Iclusig (ponatinib) through its online platform, providing expanded treatment options for patients with chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL).

The company said that Iclusig, approved in China in September 2024, has demonstrated particular efficacy against T315I-mutated BCR::ABL1 disease that is resistant to first and second generation TKIs, with the OPTIC trial showing a four-year survival rate of 88% among certain patient cohorts.

Fangzhou's drug supply chain spans multiple therapeutic areas including oncology, liver disease and cardiovascular, and it now offers over 210,000 drug SKUs to meet the diverse needs of chronic disease patients.